LC-MS/MS Profiles a Lasting AMD Eye Therapy

When cells get stressed, they trigger a built-in repair system called the unfolded protein response (UPR), and scientists have found that this system plays a role in several eye conditions, including age-related macular degeneration (AMD), a leading cause of vision loss in older adults. One promising treatment approach involves a small protein fragment called mini-cry, derived from a natural eye protein, that helps cells manage this stress response and keep things running smoothly. The problem is that because the fragment is so small, it gets cleared out of the eye very quickly, long before it can do much good.

To help it stay around longer, researchers attached mini-cry to a special class of materials called elastin-like polypeptides (ELPs). These are unique in that they respond to temperature by clumping together into tiny droplet-like structures, almost like a gel forming right at the injection site. Provided that this attachment does not interfere with mini-cry's ability to work, the combined molecule could stay in the eye much longer, thus potentially providing a more lasting therapeutic benefit.

That idea led to this study, where researchers compared two different versions of this combined molecule, designed to form these tiny droplet clusters after being injected directly into the eye. To understand what was happening at a molecular level, they used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to allow them to get a detailed snapshot of how the treatments were affecting the eye's protein makeup. A paper based on their efforts was published in the journal Drug Delivery and Translational Research.¹

What Is Age-related Macular Degeneration (AMD)?

AMD is one of the top causes of serious vision loss in older adults, and experts predict it will affect nearly 288 million people worldwide by 2040.² A disease that gradually damages a key layer of cells in the back of the eye, eventually leading to permanent vision loss,^3,4 there are two main types of AMD, dry and wet. The dry form is the more gradual of the two, starting with the buildup of tiny deposits under the retina and a slow decline in the health of that critical cell layer, eventually progressing to a more advanced stage called geographic atrophy, where vision loss becomes permanent.⁵

How Well Does Cry-V96 Perform in Laboratory, Cellular, and Animal Testing?

The researchers ran the treatment through a series of tests to see how well it worked. First, they checked its ability to prevent a problematic protein called tau from clumping together, something that is linked to various disease processes. One version of the treatment, called cry-V96, stood out as noticeably better at both stopping new clumps from forming and breaking apart clumps that had already formed.¹

Next, they tested how well the treatments could calm down cellular stress in eye cells, using a chemical to deliberately trigger that stress response in the lab. Both versions of the treatment were able to dial down the stress signaling pathway, but again, cry-V96 did the best job of easing that internal stress response.¹

Third, the team looked at how well the treatment got into cells and where it ended up once inside. Compared to untreated cells, the treated ones showed better uptake and stronger association with cellular structures, and interestingly, the treatment tended to move into the cell's nucleus specifically when the cells were under stress.¹

From there, the researchers tested the best-performing version, cry-V96, in live rabbit eyes. After being injected, it formed a slow-releasing deposit that stuck around in the eye for an extended period, and importantly, imaging scans showed no signs that it was causing any damage or toxicity to the eye.¹

Finally, using their specialized protein-analysis technique, the researchers identified 59 proteins that showed up in noticeably higher amounts specifically in eyes treated with cry-V96. Those proteins pointed to biological processes involved in keeping proteins properly folded and functional, moving materials around inside cells, and helping cells adapt to stress.¹

“Collectively,” write the authors of the paper,¹ “these findings establish cry-ELPs as multifunctional molecules that combine potent chaperone activity with sustained ocular delivery, providing a promising strategy for targeting UPR dysregulation in AMD and related degenerative diseases.”

Read More on Similar Topics
Using Chromatography to Determine Structure and Development of the Eye Lens

References

1. Attia, S. A.; Tse, A. M.; Ramirez, A. D. et al. αB-crystallin elastin-like Polypeptides for Sustained Ocular Drug Delivery. Drug Deliv Transl Res. 2026.DOI: 10.1007/s13346-026-02210-w
2. Fleckenstein, M.; Schmitz-Valckenberg, S.; Chakravarthy. U. Age-Related Macular Degeneration: A Review. JAMA 2024, 331 (2), 147-157. DOI: 10.1001/jama.2023.26074
3. Lin, J. H.; Lavail, M. M. Misfolded Proteins and Retinal Dystrophies. Adv Exp Med Biol. 2010, 664, 115-121. DOI: 10.1007/978-1-4419-1399-9_14
4. McLaughlin, T.; Medina, A.: Perkins, J. et al. Cellular Stress Signaling and the Unfolded Protein Response in Retinal Degeneration: Mechanisms and Therapeutic Implications. Mol Neurodegeneration 2022, 17 (1), 25. DOI: 10.1186/s13024-022-00528-w
5. Thomas, C. J.; Mirza, R. G.; Gill, M. K. Age-Related Macular Degeneration. Med Clin North Am. 2021, 105 (3), 473-491. DOI: 10.1016/j.mcna.2021.01.003